Leerink Partnrs Has Negative Outlook of FULC Q1 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Research analysts at Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.35) per share for the quarter, down from their prior forecast of ($0.30). The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.32) EPS and FY2026 earnings at ($1.19) EPS.

FULC has been the topic of several other research reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. HC Wainwright restated a “neutral” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.33.

Fulcrum Therapeutics Trading Up 1.5 %

FULC stock opened at $3.37 on Friday. The company has a fifty day simple moving average of $4.12 and a 200 day simple moving average of $4.61. Fulcrum Therapeutics has a 1 year low of $2.86 and a 1 year high of $13.70. The firm has a market cap of $181.77 million, a PE ratio of -10.87 and a beta of 2.03.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03).

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. lifted its holdings in shares of Fulcrum Therapeutics by 223.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock valued at $2,032,000 after purchasing an additional 393,202 shares in the last quarter. State Street Corp lifted its stake in Fulcrum Therapeutics by 61.4% in the 3rd quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after acquiring an additional 638,955 shares in the last quarter. Barclays PLC lifted its stake in Fulcrum Therapeutics by 367.1% in the 3rd quarter. Barclays PLC now owns 124,141 shares of the company’s stock valued at $443,000 after acquiring an additional 97,565 shares in the last quarter. Braidwell LP acquired a new position in Fulcrum Therapeutics during the 3rd quarter worth approximately $3,817,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Fulcrum Therapeutics during the 3rd quarter worth approximately $474,000. 89.83% of the stock is owned by institutional investors and hedge funds.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.